Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCCAM on echinacea

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary & Alternative Medicine has revised its website "to correct erroneous statements [NCCAM] had made previously" about a study on low-dose echinacea, the NIH center announces Oct. 12. The American Herbal Products Association suggested in an Oct. 4 letter to NCCAM Director Stephen Straus that the revisions be made (1"The Tan Sheet" Oct. 10, 2005, In Brief). The revisions include the removal of the sentence "what's on the label may not always be what's in the bottle," as well as a statement made by Straus endorsing the echinacea study critics felt was inconclusive. NCCAM also added a disclaimer statement as well as one clarifying the dosage used in the trial. The study appeared in the July 28 New England Journal of Medicine (2"The Tan Sheet" Aug. 1, 2005, p. 13)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel